Literature DB >> 17981917

Observed and expected frequency of comorbid chronic diseases in rheumatic patients.

E Loza1, J A Jover, L Rodriguez-Rodriguez, L Carmona.   

Abstract

OBJECTIVE: To estimate and compare the observed and expected prevalence of the co-existence of rheumatic diseases (RD) with other chronic conditions.
METHODS: The self-reported diagnosis of chronic conditions was obtained from the 2192 participants in a national health survey (Spain, 1999-2000) We compared the estimated prevalence of the co-existence of a RD with other chronic conditions, to the expected prevalence using two-sample test of proportion.
RESULTS: The observed (O) prevalence was significantly higher than expected (E) in the following combination of self-reported diseases: RD+arterial hypertension (O/E ratio = 1.88), RD+diabetes mellitus (O/E ratio = 2.07), RD+hypercholesterolemia (O/E ratio = 1.87), RD+cardiological (O/E ratio = 1.83), and RD+digestive diseases (O/E ratio = 2.07). The prevalence of selected co-existent pairs of diseases is more frequent with increasing age and differs between women and men.
CONCLUSIONS: The excess in prevalence of some combinations of diseases may serve as a reminder to the rheumatologists that many of their patients will have co-existent disease of which they need to be aware to properly plan their management. It may also be a sign of common risk factors between diseases or of adverse events.

Entities:  

Mesh:

Year:  2007        PMID: 17981917     DOI: 10.1136/ard.2007.078659

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  8 in total

1.  Fifteen-year trend in information on the World Wide Web for patients with rheumatoid arthritis: evolving, but opportunities for improvement remain.

Authors:  Jose Dionisio Castillo-Ortiz; Jose de Jesus Valdivia-Nuno; Andrea Ramirez-Gomez; Heber Garagarza-Mariscal; Carlos Gallegos-Rios; Gabriel Flores-Hernandez; Luis Hernandez-Sanchez; Victor Brambila-Barba; Jose Juan Castaneda-Sanchez; Zalathiel Barajas-Ochoa; Angel Suarez-Rico; Jorge Manuel Sanchez-Gonzalez; Cesar Ramos-Remus
Journal:  Rheumatol Int       Date:  2016-06-13       Impact factor: 2.631

2.  Increased occurrence of cardiovascular events and comorbidities in a general rheumatology cohort.

Authors:  A Mohammad; K Hartery; U Bond; M Phelan
Journal:  Ir J Med Sci       Date:  2010-02-26       Impact factor: 1.568

3.  Association of rheumatic diseases with early exit from paid employment in Portugal.

Authors:  Pedro A Laires; Miguel Gouveia
Journal:  Rheumatol Int       Date:  2014-01-31       Impact factor: 2.631

4.  Prevalence and impact of non-cardiovascular comorbidities among older adults hospitalized for non-ST segment elevation acute coronary syndrome.

Authors:  Richard Ofori-Asenso; Ella Zomer; Ken Lee Chin; Peter Markey; Si Si; Zanfina Ademi; Andrea J Curtis; Sophia Zoungas; Danny Liew
Journal:  Cardiovasc Diagn Ther       Date:  2019-06

5.  Cross-sectional examination of musculoskeletal conditions and multimorbidity: influence of different thresholds and definitions on prevalence and association estimates.

Authors:  Dianne B Lowe; Michael J Taylor; Sophie J Hill
Journal:  BMC Res Notes       Date:  2017-01-18

6.  Associations between multimorbidity and additional burden for working-age adults with specific forms of musculoskeletal conditions: a cross-sectional study.

Authors:  Dianne B Lowe; Michael J Taylor; Sophie J Hill
Journal:  BMC Musculoskelet Disord       Date:  2017-04-04       Impact factor: 2.362

7.  The impact of different rheumatic diseases on health-related quality of life: a comparison with a selected sample of healthy individuals using SF-36 questionnaire, EQ-5D and SF-6D utility values.

Authors:  Fausto Salaffi; Marco Di Carlo; Marina Carotti; Sonia Farah; Alessandro Ciapetti; Marwin Gutierrez
Journal:  Acta Biomed       Date:  2019-01-15

8.  Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study.

Authors:  Javier Rivera; Miguel A Vallejo
Journal:  Rheumatol Int       Date:  2016-09-23       Impact factor: 2.631

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.